linkedin
BROUGHT TO YOU BY
Exclusive Access, Inclusive Growth

WELCOME TO ET PRIME

BROUGTH TO YOU BY
Exclusive Access, Inclusive Growth
ET Prime
Strategy

Ajanta Pharma has a way with out-of-the-box ideas. It needs one again to beat its mid-life blues.

Close study of markets, contrarian calls, and clinical execution — in the past, these have helped Ajanta Pharma sail through when the rest of the sector was struggling. A listless home market, loss of a key Africa business, and a stringent regulatory watch are posing challenges for it again. Can it hit upon a formula for rejuvenation once more?
font size
FONT SIZE
save
SAVE
saved
SAVED
Gift this article
GIFT ARTICLE
By
29 Jan 2020 9 Mins Read 1 comments
From left, Rajesh Agrawal, Joint MD, Ajanta Pharma; Yogesh Agrawal, MD, Ajanta Pharma and Nitin Gadkari, Minister of Road Transport and Highways of India ; courtesy of Ajanta Pharma via Facebook
From left, Rajesh Agrawal, Joint MD, Ajanta Pharma; Yogesh Agrawal, MD, Ajanta Pharma and Nitin Gadkari, Minister of Road Transport and Highways of India ; courtesy of Ajanta Pharma via Facebook
Remember Jitendra, the age-defying boisterous Bollywood actor in the TV ads for 30+ tablets? Those in their forties and a little more will likely do. Its owner, Mumbai-based Ajanta Pharma, did a roaring business from this uniquely positioned, energy-boosting OTC drug. But India’s pharma sector is like a herd. So, 30+ was soon besieged by a host of
Ajanta, and return ratios are likely to improve. The R&D is ready, the products are being selected, and the plants are almost complete. But now the wait is for the growth cycle to return. Ajanta Pharma needs a dose of the medicine that made it famous — a 30+ to rejuvenate the 40-plus company. ( Graphics by Mohammad Arshad)
Remember Jitendra, the age-defying boisterous Bollywood actor in the TV ads for 30+ tablets? Those in their forties and a little more will likely do. Its owner, Mumbai-based Ajanta Pharma, did a roaring business from this uniquely positioned, energy-boosting OTC drug. But India’s pharma sector is like a herd. So, 30+ was soon besieged by a host of Ajanta, and return ratios are likely to improve. The R&D is ready, the products are being selected, and the plants are almost complete. But now the wait is for the growth cycle to return. Ajanta Pharma needs a dose of the medicine that made it famous — a 30+ to rejuvenate the 40-plus company. ( Graphics by Mohammad Arshad)

The latest from ET Prime is now on Telegram. To subscribe to our Telegram newsletter click here.

Gift this story

YOU CAN GIFT 0 MORE STORIES THIS MONTH

Maximum 10 Email IDs allowed

300 characters remaining

Gift Sent Successfully

Limit Reached
Limit Reached

You’ve gifted all the 0 articles from your monthly gift bucket!

Please come back next month.

0 more articles will be waiting for you in your gift bucket.

CONTRIBUTORS WHO HAVE COMMENTED ON THIS STORY

test

user Krishna Sinha Industrial Adviser Retired GoI, Keen observer of international economic relation

Current Edition

China’s titanic challenge: curing virus-stricken economy
Economy

China’s titanic challenge: curing virus-stricken economy

The government office overseeing efforts to control the spread of the Covid-19 virus has called for an orderly resumption of business, but a full recovery will take some time. With China’s production system relying on millions of migrant workers, factories are struggling to simultaneously repopulate factory floors and limit the risks of contagion.

[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]